Scientific Reports (May 2021)

Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors

  • Robert Terziev,
  • Dimitri Psimaras,
  • Yannick Marie,
  • Loic Feuvret,
  • Giulia Berzero,
  • Julian Jacob,
  • Caroline Dehais,
  • Flavie Bompaire,
  • Wolf Mueller,
  • Ben Kinnersley,
  • Jean-Yves Delattre,
  • Ahmed Idbaih,
  • Khe Hoang-Xuan,
  • Marc Sanson,
  • Damien Ricard

DOI
https://doi.org/10.1038/s41598-021-89216-1
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 9

Abstract

Read online

Abstract The incidence and risk factors associated with radiation-induced leukoencephalopathy (RIL) in long-term survivors of high-grade glioma (HGG) are still poorly investigated. We performed a retrospective research in our institutional database for patients with supratentorial HGG treated with focal radiotherapy, having a progression-free overall survival > 30 months and available germline DNA. We reviewed MRI scans for signs of leukoencephalopathy on T2/FLAIR sequences, and medical records for information on cerebrovascular risk factors and neurological symptoms. We investigated a panel of candidate single nucleotide polymorphisms (SNPs) to assess genetic risk. Eighty-one HGG patients (18 grade IV and 63 grade III, 50M/31F) were included in the study. The median age at the time of radiotherapy was 48 years old (range 18–69). The median follow-up after the completion of radiotherapy was 79 months. A total of 44 patients (44/81, 54.3%) developed RIL during follow-up. Twenty-nine of the 44 patients developed consistent symptoms such as subcortical dementia (n = 28), gait disturbances (n = 12), and urinary incontinence (n = 9). The cumulative incidence of RIL was 21% at 12 months, 42% at 36 months, and 48% at 60 months. Age > 60 years, smoking, and the germline SNP rs2120825 (PPARg locus) were associated with an increased risk of RIL. Our study identified potential risk factors for the development of RIL (age, smoking, and the germline SNP rs2120825) and established the rationale for testing PPARg agonists in the prevention and management of late-delayed radiation-induced neurotoxicity.